What is VCEL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VCEL?

P/E (TTM) is 84.67 and 52-week range is $28.95 to $49.32 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VCEL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VCEL?

The company profile lists revenue (TTM) near $299M, net income (TTM) near $24M, EPS (TTM) near $0.42 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vericel Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 51.1M shares outstanding, ISIN US92346J1088 when available from company profile and filing metadata.

Vericel Corp

$VCEL

Health Care · Biotechnology

IR Run Scenarios

$40.10

+0.12%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 398 full-time employees. The company has a differentiated portfolio of cell therapy and specialty biologic products. The company markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The firm also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.

Employees

398

Website

vcel.com/

IPO

1997-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)